Kinetics and Mechanism of Interaction of cis-Diaquabis(oxalato)chromate(III) with Cefoperazone in Aqueous Medium: as an Antibacterial Study

  • Jashoda BeheraEmail author
  • Bharati Behera
Original Article



Chromium species in higher oxidation states are toxic and carcinogenic. But lower oxidation state as Cr(III) microelement shows potential antimicrobial properties. Cefoperazone sodium is a parenteral bactericidal third-generation cephalosporin antibiotic effective in treating Pseudomonas bacterial infections. A new drug formed with the complexation of metal and drug. Hence, newer coordinated drugs were explored that can also show the antimicrobial effectiveness similar to free drug.


cis-[Cr(C2O4)2(H2O)2] was synthesized by the proposed method and its complexation with cefoperazone was done by reflux for 5–6 h with stirring. The structure was characterized by spectroscopic techniques (UV, IR, mass, and AAS). The antimicrobial study was done using agar disk-diffusion method. The interaction of the ligand substitution reaction between cis-[Cr(C2O4)2(H2O)2] and cefoperazone (CFZ) has been investigated in aqueous medium. The reaction has been found to proceed by depending on ligand concentration.


The kinetic reaction was studied at [CFZ] varied from 1.50 × 10−2 mol dm−3 to 4.50 × 10−2 mol dm−3 with pH variation from 3.0 to 5.0. The rate of reaction is found to increase in [H+] and [CFZ]. The activation parameters ΔH# and ΔS# are found to be 42.72 kJ mol−1 and − 182.41 J K−1 mol−1 respectively. The positive values of activation enthalpy (ΔH#) shows that the decomposition process is endothermic.


Compared to the free cefoperazone, complexation with chromium(III) metal ion shows similar antimicrobial activity. The reaction takes place through an associative interchange mechanism.


Cr(III) complex Cefoperazone Substitution reaction Kinetic study Antimicrobial study 



The authors thank UGC, Government of India, New Delhi for providing UGC-BSR (Basic Science Research) Fellowship. We are grateful to Central Drug Research Institute, Lucknow for supporting CHN and mass analysis, and Sri Vasavi Institute of Pharmaceutical Sciences, Tadepaligudem, Andhra Pradesh for Antimicrobial study.


  1. 1.
    Vincent JB. The bioinorganic chemistry of chromium (III). Polyhedron. 2001;20:1–26.CrossRefGoogle Scholar
  2. 2.
    Yamamoto A, Wada O, Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem. 1987;165:627–31.CrossRefGoogle Scholar
  3. 3.
    Szablowicz M, Kita E. New chromium(III)-nicotinate complexes. Kinetics and mechanism of nicotinate ligand liberation in acidic media. Transit Met Chem. 2005;30:623–9.CrossRefGoogle Scholar
  4. 4.
    Behera B, Behera J. Drug metal ion interaction: kinetics and mechanism of interaction of cis-bis (oxalate)diaquochromium(III) ion with ampicillin in aqueous medium. Chem Sci Trans. 2017;6(4):535–44.Google Scholar
  5. 5.
    Baral D, Rout S, Behera J, Si S, Mohanty P. Kinetics and mechanism of interaction of hexaaquachromium (III) with L-dopa in aqueous medium: comparative antiparkinsonian studies. Transit Met Chem. 2011;36:231–6.CrossRefGoogle Scholar
  6. 6.
    Zavitsanos K, Petrou AL. Kinetics and mechanisms of the chromium(III) reactions with 2,4- and 2,5-dihydroxybenzoic acids in weak acidic aqueous solutions. Bioinorg Chem Appl. 2010;2010:1–10.CrossRefGoogle Scholar
  7. 7.
    Thoma V, Tampouris K, Petrou AL. Kinetics and mechanism of the reaction between chromium(III) and 3,4-dihydroxy-phenyl-propenoic acid (caffeic acid) in weak acidic aqueous solutions. Bioinorg Chem Appl. 2008;2008:1–7.CrossRefGoogle Scholar
  8. 8.
    Messih MF. Kinetics and mechanism of interaction between chromium(III) and ethylenediaminetetra-3-propinate in aqueous acidic media. Adv Chem Eng Sci. 2013;3:98–104.CrossRefGoogle Scholar
  9. 9.
    Sorenson JRJ. Copper chelates as possible active forms of the antiarthritic agents. J Med Chem. 1976;19:135–41.CrossRefGoogle Scholar
  10. 10.
    Brown DH, Smith WE, Teape JW. Antiinflammatory effects of some copper complexes. J Med Chem. 1980;23:729–33.CrossRefGoogle Scholar
  11. 11.
    Bergan T. Pharmacokinetic properties of the cephalosporins. Drugs. 1987;34:89–104.CrossRefGoogle Scholar
  12. 12.
    Cunha BA. Third-generation cephalosporins: a review. Clin Ther. 1982;14:616–52.Google Scholar
  13. 13.
    Chin NX, Gu JW, Fang W, Neu HC. In vitro activity and beta-lactamase stability of GR69153, a new long-acting cephalosporin. Antimicrob Agents Chemother. 1991;35:259–66.CrossRefGoogle Scholar
  14. 14.
    Fu KP, Foleno BD, Lafredo SC, LoCoco JM, Isaacson DM. In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1993;37:301–7.CrossRefGoogle Scholar
  15. 15.
    Parfitt K. The complete drug reference: a Martindale. 33rd ed. London: The Pharmaceutical Press; 2002.Google Scholar
  16. 16.
    Kalman D, Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. Tex Heart Inst J. 1990;17:203–15.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Al-Delaimy WK, Willet WC, Manson JE, Speizer FE, Hu FB. Smoking and mortality among women with type 2 diabetes: the Nurses’ Health Study cohort. Diabetes Care. 2001;24:2043–8.CrossRefGoogle Scholar
  18. 18.
    Al-Delaimy WK, Manson JE, Willett WC, Stampfer MJ, Hu FB. Snoring as a risk factor for type II diabetes mellitus: a prospective study. Am J Epidemiol. 2002;155:387–93.CrossRefGoogle Scholar
  19. 19.
    Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–20.CrossRefGoogle Scholar
  20. 20.
    Islam MS, Farooque MA, Bodruddoza MAK, Mosaddik MA, Alam MS. Antimirobial and toxicological studies of mixed ligand transition metal complexes of Schiff bases. J Biol Sci. 2002;2:797–9.CrossRefGoogle Scholar
  21. 21.
    Singh DP, Kumar R, Malik V, Tyagi P. Template synthesis, spectroscopic studies and biological activities of macrocyclic complexes derived from thiocarbohydrazide and glyoxal. J Enzyme Inhib Med Chem. 2007;22:177–82.CrossRefGoogle Scholar
  22. 22.
    Sakagami N, Kita E, Kita P, Winsniewska J, Kaizaki S. The crystal structures of bis(oxalato)chromium(III) complexes with histamine and B6 vitamin: Na[Cr(ox)2(hm)]·3H2O and Na[Cr(ox)2(PM)]·H2O (hm, histamine; PM, pyridoxamine). Polyhedron. 1999;18:2001–7.CrossRefGoogle Scholar
  23. 23.
    Anacona JR, Bravo A, Lopez ME. Antibacterial activity of cefoperazone metal complexes. Lt Am J Pharm. 2012;31:27–31.Google Scholar
  24. 24.
    Dash SC, Das NN, Mohanty P. Kinetics and mechanism of the reaction of ranitidine hydrochloride with trans-(diaqua) (N,N’-ethylene-bis-salicylamide) chromium(III) and hexa-aquachromium(III) ion – a comparative study. Indian J Chem Technol. 2011;18:132–6.Google Scholar
  25. 25.
    Debnath A, Hussain F, Masram DT. Synthesis, characterisation, and antifungal studies of Cr(III) complex of norfloxacin and bipiridyl ligand. Bioinorg Chem Appl. 2014;2014:1–7.CrossRefGoogle Scholar
  26. 26.
    Anacona JR, Gil CC. Synthesis and antibacterial activity of cefoxitin metal complexes. Transit Met Chem. 2005;30:605–9.CrossRefGoogle Scholar
  27. 27.
    Anacona JR, Acosta F. Synthesis and antibacterial activity of cephradine metal complexes. J Coord Chem. 2006;59:621–7.CrossRefGoogle Scholar
  28. 28.
    Brauer G. Handbook of preparative inorganic chemistry. 2nd ed. Newyork, London: Academic Press; 1965. vol 2. pp. 1372.Google Scholar
  29. 29.
    Schenk C, Stieger H, Kelm H. Kinetik und Mechanismen der Bildungsreaktionen der Aquo-Oxalato-Chrom(III)-Komplexionen in wäßrigen Lösungen. Z Anorg Allg Chem. 1972;391:1–10.CrossRefGoogle Scholar
  30. 30.
    Frost AA, Peasron RG. Kinetics and mechanism. New York: Wiley; 1961.Google Scholar
  31. 31.
    Franchini GC, Giusti A, Preti C, Tosi L, Zannini P. Cefoperazone (Hcefopz) interacts with transition metal(II) ions to give [M(cefopz)Cl] complexes (M=Fe, Co, Ni, Cu and Cd) and [Fe(cefopz)Cl]Cl which were characterized by physicochemical and spectroscopic methods. Polyhedron. 1985;9:1553–8.CrossRefGoogle Scholar
  32. 32.
    Hadjikostas CC, Katsoulos GA, Shakhatreh SK. Synthesis and spectral studies of some new palladium(II) and platinum(II) dithiocarbimato complexes. Reactions of bases with the corresponding N alkyldithiocarbamates. Inorg Chim Acta. 1987;133:129–32.CrossRefGoogle Scholar
  33. 33.
    Castillo M, Criado JJ, Macias B, Vaquero MV. Chemistry of dithio-carbamate derivatives of amino acids. I. Study of some dithiocarbamate derivatives of linear α-amino acids and their nickel(II) complexes. Inorg Chim Acta. 1986;124:127–32.CrossRefGoogle Scholar
  34. 34.
    Lutfullah SS, Rahman N, Azmi SNH, Iqbal B, Amburk MIBB, Bait MIB, et al. UV spectrophotometric determination of Cu(II) in synthetic mixture and water samples. J Chin Chem Soc. 2010;57:622–31.CrossRefGoogle Scholar
  35. 35.
    Mashaly MM, Abd-Elwahab ZH, Faheim AA. Preparation, spectral characterization and antimicrobial activities of Schiff base complexes derived from 4-aminoantipyrine. Mixed ligand complexes with 2-aminopyridine, 8-hydroxyquinoline and oxalic acid and their pyrolytical products. J Chin Chem Soc. 2004;51:901–15.CrossRefGoogle Scholar
  36. 36.
    Barnes DJ, Chapman RL, Stephens FS, Vagg RS. Studies on the metal amide bond. VII. Metal complexes of the flexible N4 ligand N,N′-bis(2′-pyridinecarboxamide)1,2-ethane. Inorg Chim Acta. 1981;51:155–62.CrossRefGoogle Scholar
  37. 37.
    Garg BS, Bhojak N, Dwivedi P, Kumar V. Copper(II) complexes of acid amide derivatives of 2-aminopyridine and an exogenous ligand. Transit Met Chem. 1999;24:463–6.CrossRefGoogle Scholar
  38. 38.
    Patel AK, Patel JC, Dholariya HR, Patel KS, Patel VK, Patel KD. Synthesis, characterization and biological evaluation: copper(II) complexes of hydroxy coumarins with ciprofloxacin research. Res J Pharm, Bio And Chem Sci. 2013;4:564–79.Google Scholar
  39. 39.
    Anacona JR, Osorio I. Synthesis and antibacterial activity of copper(II) complexes with sulphathiazole and cephalosporin ligands. Transit Met Chem. 2008;33:517–21.CrossRefGoogle Scholar
  40. 40.
    Patel KS, Patel JC, Dholariya HR, Patel VK, Patel KD. Synthesis of Cu(II), Ni(II), Co(II), and Mn(II) Complexes with ciprofloxacin and their evaluation of antimicrobial, antioxidant and anti-tubercular activity. O. J. Metal. 2012;2:49–59.Google Scholar
  41. 41.
    Bootwala S, Tariq M, Somasundaran S, Aruna K. Synthesis, spectroscopic and biological characterization of some transition metal complexes with ethyl 2-{[(2e, 3 Z)-4-hydroxypent-3-en-2-ylidene] amino}-4, 5, 6, 7-tetrahydro-1-benzothiophene-3 carboxylate. Int J Pharm Bio Sci. 2013;3:345–54.Google Scholar
  42. 42.
    Alekseev VG. Drug synthesis methods and production technologies metal complexes of penicillins and cephalosporins (review). Pharm Chem J. 2012;45:679–97.CrossRefGoogle Scholar
  43. 43.
    Obeidat M, Shatnawi M, Al-alawi M, Al-Zu’bi E, Al-Dmoor H, Al-Qudah M, et al. Antimicrobial activity of crude extracts of some plant leaves. Res J Microbiol. 2012;7:59–67.CrossRefGoogle Scholar
  44. 44.
    Shungu DL, Weinberg E, Gadebusch HH. Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-75). Antimicrob Agents Chemother. 1983;23:256–60.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of ChemistryUtkal UniversityBhubaneswarIndia

Personalised recommendations